Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ravulizumab in adults with immunoglobulin A nephropathy
jRCT2041240015Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Ravulizumab IV q8w with Placebo IV q8w (2 arms). Primary endpoints: Change from baseline in proteinuria based on 24-hour urine protein creatinine ratio at Week 34 and Change from baseline in glomerular filtration rate at Week 106. Started Apr 2024; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2041240015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240015.